Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Protein pathway involved in brain tumor stem cell growth identified

  • Altering perception of feeding state may promote healthy aging

  • Left or right? The brain knows before you move

  • High stress for new mothers increases secondhand smoke risk for infants

  • Physician-industry conflict of interest issue from MS patient perspective

  • Enhancing studies on a possible blood biomarker for traumatic brain injury

  • Employees become angry when receiving after-hours email, texts

  • Study challenges theory on unconscious memory system in the brain

  • Aggressive boys tend to develop into physically stronger teens

  • Bumblebees make false memories, too

  •